CBDL.D Stock Overview
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
CBD Life Sciences Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0069 |
52 Week High | US$0.03 |
52 Week Low | US$0.0003 |
Beta | 0 |
1 Month Change | -77.00% |
3 Month Change | -77.00% |
1 Year Change | 2,200.00% |
3 Year Change | -98.08% |
5 Year Change | -99.79% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
CBDL.D | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -8.0% | 3.0% | -0.7% |
1Y | 2,200.0% | 12.5% | 22.8% |
Return vs Industry: CBDL.D exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: CBDL.D exceeded the US Market which returned 22.3% over the past year.
Price Volatility
CBDL.D volatility | |
---|---|
CBDL.D Average Weekly Movement | 7,057.9% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CBDL.D's share price has been volatile over the past 3 months.
Volatility Over Time: CBDL.D's weekly volatility has decreased from 7690% to 7058% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 6 | Lisa Nelson | lbcbioscienceinc.com |
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.
CBD Life Sciences Inc. Fundamentals Summary
CBDL.D fundamental statistics | |
---|---|
Market cap | US$1.04m |
Earnings (TTM) | -US$3.22m |
Revenue (TTM) | US$138.19k |
0.0x
P/S Ratio0.0x
P/E RatioIs CBDL.D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CBDL.D income statement (TTM) | |
---|---|
Revenue | US$138.19k |
Cost of Revenue | US$73.52k |
Gross Profit | US$64.67k |
Other Expenses | US$3.28m |
Earnings | -US$3.22m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did CBDL.D perform over the long term?
See historical performance and comparison